Gene Tx For Renal Disease With Purespring CEO Richard Francis
Business Of Biotech · 57 minutes ·

Gene Tx For Renal Disease With Purespring CEO Richard Francis

Purespring Therapeutics launched in 2020 on the back of IP developed by renowned kidney researcher Prof. Moin Saleem, who spent decades working on podocytes when podocytes weren’t cool. Just two years later, the company boasts three gene therapy assets and a platform developed expressly to identify new therapeutic targets to address kidney disease. These assets promise to change the "dialysis or transplant" ultimatums associated with kidney disease, where therapeutic innovation has been scarce. Under the leadership of CEO Richard Francis, the young company is operating with the audacious goal to take its therapeutics all the way to the commercial finish line. On this episode of the Business of Biotech, Francis offers a transparent look at the company’s growth strategy and the progress it’s achieved to date.

Comments (0)

You Must Be Logged In To Comment

Similar podcasts

Life Sciences Connect

Explore Life Sciences

Management Information Science

Centre for Law, Medicine and Life Sciences Lectures

Biological sciences

Medical Sciences

Cambridge Judge Business School Discussions on Management Science & Operations